Which has preferable earnings and valuation, OABI or ALMR?

Alamar Biosciences has higher revenue and earnings than OmniAb. Alamar Biosciences is trading at a lower price-to-earnings ratio than OmniAb, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OmniAb $18.67M 34.66 -$64.78M -$0.36 N/A Alamar Biosciences $74.21M 32.59 -$29.82M -$1.96 N/A

Does the media refer more to OABI or ALMR?

In the previous week, Alamar Biosciences had 1 more articles in the media than OmniAb. MarketBeat recorded 3 mentions for Alamar Biosciences and 2 mentions for OmniAb. OmniAb's average media sentiment score of 0.60 beat Alamar Biosciences' score of 0.34 indicating that OmniAb is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OmniAb 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alamar Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer MRVI or OABI?

In the previous week, Maravai LifeSciences and Maravai LifeSciences both had 2 articles in the media. OmniAb's average media sentiment score of 0.60 beat Maravai LifeSciences' score of 0.25 indicating that OmniAb is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Maravai LifeSciences 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral OmniAb 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, PSNL or OABI?

OmniAb has lower revenue, but higher earnings than Personalis. Personalis is trading at a lower price-to-earnings ratio than OmniAb, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Personalis $69.65M 24.66 -$81.27M -$1.09 N/A OmniAb $18.67M 34.66 -$64.78M -$0.36 N/A

Is PSNL or OABI more profitable?

OmniAb has a net margin of -115.12% compared to Personalis' net margin of -153.84%. OmniAb's return on equity of -16.59% beat Personalis' return on equity. Company Net Margins Return on Equity Return on Assets Personalis -153.84% -46.47% -35.30% OmniAb -115.12% -16.59% -14.82%

Does the media favor PSNL or OABI?

In the previous week, Personalis had 1 more articles in the media than OmniAb. MarketBeat recorded 3 mentions for Personalis and 2 mentions for OmniAb. Personalis' average media sentiment score of 1.77 beat OmniAb's score of 0.60 indicating that Personalis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Personalis 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive OmniAb 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable valuation and earnings, BLFS or OABI?

BioLife Solutions has higher revenue and earnings than OmniAb. OmniAb is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioLife Solutions $106.69M 16.82 -$4.59M $1.16 31.63 OmniAb $18.67M 34.66 -$64.78M -$0.36 N/A

Is BLFS or OABI more profitable?

BioLife Solutions has a net margin of 53.29% compared to OmniAb's net margin of -115.12%. BioLife Solutions' return on equity of 2.70% beat OmniAb's return on equity. Company Net Margins Return on Equity Return on Assets BioLife Solutions 53.29% 2.70% 2.49% OmniAb -115.12% -16.59% -14.82%

Does the media prefer BLFS or OABI?

In the previous week, OmniAb had 1 more articles in the media than BioLife Solutions. MarketBeat recorded 2 mentions for OmniAb and 1 mentions for BioLife Solutions. BioLife Solutions' average media sentiment score of 0.67 beat OmniAb's score of 0.60 indicating that BioLife Solutions is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioLife Solutions 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive OmniAb 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings & valuation, OABI or FTRE?

OmniAb has higher earnings, but lower revenue than Fortrea. Fortrea is trading at a lower price-to-earnings ratio than OmniAb, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio OmniAb $18.67M 34.66 -$64.78M -$0.36 N/A Fortrea $2.72B 0.70 -$986.20M -$0.91 N/A

Is OABI or FTRE more profitable?

Fortrea has a net margin of -3.18% compared to OmniAb's net margin of -115.12%. Fortrea's return on equity of 10.72% beat OmniAb's return on equity. Company Net Margins Return on Equity Return on Assets OmniAb -115.12% -16.59% -14.82% Fortrea -3.18% 10.72% 2.17%

Does the media refer more to OABI or FTRE?

In the previous week, Fortrea had 1 more articles in the media than OmniAb. MarketBeat recorded 3 mentions for Fortrea and 2 mentions for OmniAb. Fortrea's average media sentiment score of 0.83 beat OmniAb's score of 0.60 indicating that Fortrea is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OmniAb 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fortrea 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

OmniAb (OABI) Competitors

$4.47 +0.03 (+0.68%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$4.44 -0.03 (-0.74%)

As of 09/18/2026 07:56 PM Eastern

Compare

OABI vs. ALMR, MRVI, PSNL, BLFS, and FTRE

Should you buy OmniAb stock or one of its competitors? OmniAb's main competitors and comparable companies include Alamar Biosciences (ALMR), Maravai LifeSciences (MRVI), Personalis (PSNL), BioLife Solutions (BLFS), and Fortrea (FTRE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does OmniAb compare to Alamar Biosciences?

OmniAb (NASDAQ:OABI) and Alamar Biosciences (NASDAQ:ALMR) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, media sentiment, institutional ownership, earnings, valuation and profitability.

OmniAb presently has a consensus target price of $11.00, suggesting a potential upside of 146.09%. Alamar Biosciences has a consensus target price of $31.80, suggesting a potential downside of 8.75%. Given OmniAb's higher probable upside, equities research analysts clearly believe OmniAb is more favorable than Alamar Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OmniAb	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Alamar Biosciences	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43

Alamar Biosciences has higher revenue and earnings than OmniAb. Alamar Biosciences is trading at a lower price-to-earnings ratio than OmniAb, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OmniAb	$18.67M	34.66	-$64.78M	-$0.36	N/A
Alamar Biosciences	$74.21M	32.59	-$29.82M	-$1.96	N/A

In the previous week, Alamar Biosciences had 1 more articles in the media than OmniAb. MarketBeat recorded 3 mentions for Alamar Biosciences and 2 mentions for OmniAb. OmniAb's average media sentiment score of 0.60 beat Alamar Biosciences' score of 0.34 indicating that OmniAb is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OmniAb	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alamar Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alamar Biosciences has a net margin of 0.00% compared to OmniAb's net margin of -115.12%. Alamar Biosciences' return on equity of 0.00% beat OmniAb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OmniAb	-115.12%	-16.59%	-14.82%
Alamar Biosciences	N/A	N/A	N/A

72.1% of OmniAb shares are held by institutional investors. 9.8% of OmniAb shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Alamar Biosciences beats OmniAb on 8 of the 15 factors compared between the two stocks.

How does OmniAb compare to Maravai LifeSciences?

Maravai LifeSciences (NASDAQ:MRVI) and OmniAb (NASDAQ:OABI) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, media sentiment, analyst recommendations, earnings and valuation.

50.3% of Maravai LifeSciences shares are owned by institutional investors. Comparatively, 72.1% of OmniAb shares are owned by institutional investors. 2.5% of Maravai LifeSciences shares are owned by insiders. Comparatively, 9.8% of OmniAb shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Maravai LifeSciences and Maravai LifeSciences both had 2 articles in the media. OmniAb's average media sentiment score of 0.60 beat Maravai LifeSciences' score of 0.25 indicating that OmniAb is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Maravai LifeSciences	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
OmniAb	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

OmniAb has lower revenue, but higher earnings than Maravai LifeSciences. Maravai LifeSciences is trading at a lower price-to-earnings ratio than OmniAb, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maravai LifeSciences	$185.74M	9.74	-$130.77M	-$0.52	N/A
OmniAb	$18.67M	34.66	-$64.78M	-$0.36	N/A

Maravai LifeSciences presently has a consensus price target of $6.83, indicating a potential downside of 1.96%. OmniAb has a consensus price target of $11.00, indicating a potential upside of 146.09%. Given OmniAb's stronger consensus rating and higher probable upside, analysts plainly believe OmniAb is more favorable than Maravai LifeSciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maravai LifeSciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
OmniAb	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Maravai LifeSciences has a net margin of -37.07% compared to OmniAb's net margin of -115.12%. Maravai LifeSciences' return on equity of -15.70% beat OmniAb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Maravai LifeSciences	-37.07%	-15.70%	-8.17%
OmniAb	-115.12%	-16.59%	-14.82%

Maravai LifeSciences has a beta of 0.6, meaning that its stock price is 40% less volatile than the broader market. Comparatively, OmniAb has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market.

Summary

OmniAb beats Maravai LifeSciences on 10 of the 14 factors compared between the two stocks.

How does OmniAb compare to Personalis?

Personalis (NASDAQ:PSNL) and OmniAb (NASDAQ:OABI) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings and dividends.

OmniAb has lower revenue, but higher earnings than Personalis. Personalis is trading at a lower price-to-earnings ratio than OmniAb, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Personalis	$69.65M	24.66	-$81.27M	-$1.09	N/A
OmniAb	$18.67M	34.66	-$64.78M	-$0.36	N/A

Personalis presently has a consensus target price of $14.54, indicating a potential downside of 11.37%. OmniAb has a consensus target price of $11.00, indicating a potential upside of 146.09%. Given OmniAb's stronger consensus rating and higher probable upside, analysts plainly believe OmniAb is more favorable than Personalis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Personalis	1 Sell rating(s)	5 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.30
OmniAb	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Personalis had 1 more articles in the media than OmniAb. MarketBeat recorded 3 mentions for Personalis and 2 mentions for OmniAb. Personalis' average media sentiment score of 1.77 beat OmniAb's score of 0.60 indicating that Personalis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Personalis	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
OmniAb	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Personalis has a beta of 2.31, indicating that its stock price is 131% more volatile than the broader market. Comparatively, OmniAb has a beta of 0.62, indicating that its stock price is 38% less volatile than the broader market.

61.9% of Personalis shares are held by institutional investors. Comparatively, 72.1% of OmniAb shares are held by institutional investors. 4.2% of Personalis shares are held by company insiders. Comparatively, 9.8% of OmniAb shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

OmniAb has a net margin of -115.12% compared to Personalis' net margin of -153.84%. OmniAb's return on equity of -16.59% beat Personalis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Personalis	-153.84%	-46.47%	-35.30%
OmniAb	-115.12%	-16.59%	-14.82%

Summary

OmniAb beats Personalis on 11 of the 16 factors compared between the two stocks.

How does OmniAb compare to BioLife Solutions?

BioLife Solutions (NASDAQ:BLFS) and OmniAb (NASDAQ:OABI) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, media sentiment, institutional ownership, risk, earnings, profitability, analyst recommendations and valuation.

BioLife Solutions has a net margin of 53.29% compared to OmniAb's net margin of -115.12%. BioLife Solutions' return on equity of 2.70% beat OmniAb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioLife Solutions	53.29%	2.70%	2.49%
OmniAb	-115.12%	-16.59%	-14.82%

BioLife Solutions has a beta of 1.91, suggesting that its share price is 91% more volatile than the broader market. Comparatively, OmniAb has a beta of 0.62, suggesting that its share price is 38% less volatile than the broader market.

BioLife Solutions has higher revenue and earnings than OmniAb. OmniAb is trading at a lower price-to-earnings ratio than BioLife Solutions, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioLife Solutions	$106.69M	16.82	-$4.59M	$1.16	31.63
OmniAb	$18.67M	34.66	-$64.78M	-$0.36	N/A

BioLife Solutions presently has a consensus price target of $31.38, indicating a potential downside of 14.49%. OmniAb has a consensus price target of $11.00, indicating a potential upside of 146.09%. Given OmniAb's stronger consensus rating and higher possible upside, analysts plainly believe OmniAb is more favorable than BioLife Solutions.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLife Solutions	1 Sell rating(s)	8 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.18
OmniAb	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

93.2% of BioLife Solutions shares are owned by institutional investors. Comparatively, 72.1% of OmniAb shares are owned by institutional investors. 2.2% of BioLife Solutions shares are owned by insiders. Comparatively, 9.8% of OmniAb shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, OmniAb had 1 more articles in the media than BioLife Solutions. MarketBeat recorded 2 mentions for OmniAb and 1 mentions for BioLife Solutions. BioLife Solutions' average media sentiment score of 0.67 beat OmniAb's score of 0.60 indicating that BioLife Solutions is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioLife Solutions	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
OmniAb	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

BioLife Solutions beats OmniAb on 11 of the 17 factors compared between the two stocks.

How does OmniAb compare to Fortrea?

OmniAb (NASDAQ:OABI) and Fortrea (NASDAQ:FTRE) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation, risk and media sentiment.

72.1% of OmniAb shares are held by institutional investors. 9.8% of OmniAb shares are held by company insiders. Comparatively, 0.7% of Fortrea shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

OmniAb presently has a consensus target price of $11.00, suggesting a potential upside of 146.09%. Fortrea has a consensus target price of $22.00, suggesting a potential upside of 10.39%. Given OmniAb's higher possible upside, equities research analysts plainly believe OmniAb is more favorable than Fortrea.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OmniAb	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Fortrea	1 Sell rating(s)	5 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.36

OmniAb has higher earnings, but lower revenue than Fortrea. Fortrea is trading at a lower price-to-earnings ratio than OmniAb, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OmniAb	$18.67M	34.66	-$64.78M	-$0.36	N/A
Fortrea	$2.72B	0.70	-$986.20M	-$0.91	N/A

In the previous week, Fortrea had 1 more articles in the media than OmniAb. MarketBeat recorded 3 mentions for Fortrea and 2 mentions for OmniAb. Fortrea's average media sentiment score of 0.83 beat OmniAb's score of 0.60 indicating that Fortrea is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
OmniAb	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fortrea	1 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Fortrea has a net margin of -3.18% compared to OmniAb's net margin of -115.12%. Fortrea's return on equity of 10.72% beat OmniAb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OmniAb	-115.12%	-16.59%	-14.82%
Fortrea	-3.18%	10.72%	2.17%

OmniAb has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market. Comparatively, Fortrea has a beta of 1.97, meaning that its stock price is 97% more volatile than the broader market.

Summary

Fortrea beats OmniAb on 9 of the 16 factors compared between the two stocks.

Get OmniAb News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OABI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

OABI vs. The Competition

Export

Metric	OmniAb	Life Sciences Tools & Services Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$642.84M	$10.48B	$7.25B	$13.14B
Dividend Yield	N/A	1.46%	2.57%	12.30%
P/E Ratio	-12.42	70.70	275.79	25.40
Price / Sales	34.66	108.70	695.58	114.44
Price / Cash	N/A	27.34	77.42	51.66
Price / Book	2.42	5.70	10.46	6.33
Net Income	-$64.78M	$56.67B	$3.49B	$358.33M
7 Day Performance	9.83%	4.59%	0.59%	1.12%
1 Month Performance	6.68%	1.52%	-2.01%	-2.67%
1 Year Performance	177.64%	28.13%	18.09%	6.01%

OmniAb Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
OABI OmniAb	2.96 of 5 stars	$4.47 +0.7%	$11.00 +146.1%	+169.3%	$642.84M	$18.67M	N/A	89
ALMR Alamar Biosciences	1.5385 of 5 stars	$29.95 -2.8%	$31.80 +6.2%	N/A	$2.14B	$100.42M	N/A	222
MRVI Maravai LifeSciences	1.2952 of 5 stars	$7.19 -1.8%	$6.25 -13.1%	+142.0%	$1.90B	$208.78M	N/A	610	News Coverage
PSNL Personalis	2.1469 of 5 stars	$16.60 -3.5%	$14.54 -12.4%	+181.8%	$1.80B	$69.65M	N/A	400
BLFS BioLife Solutions	2.4694 of 5 stars	$35.38 +0.4%	$31.38 -11.3%	+39.6%	$1.72B	$96.21M	30.50	440

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:OABI) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

OmniAb (OABI) Competitors

OABI vs. ALMR, MRVI, PSNL, BLFS, and FTRE

How does OmniAb compare to Alamar Biosciences?

Summary

How does OmniAb compare to Maravai LifeSciences?

Summary

How does OmniAb compare to Personalis?

Summary

How does OmniAb compare to BioLife Solutions?

Summary

How does OmniAb compare to Fortrea?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OABI vs. The Competition

OmniAb Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

OmniAb (OABI) Competitors

OABI vs. ALMR, MRVI, PSNL, BLFS, and FTRE

How does OmniAb compare to Alamar Biosciences?

Do analysts recommend OABI or ALMR?

Which has preferable earnings and valuation, OABI or ALMR?

Does the media refer more to OABI or ALMR?

Is OABI or ALMR more profitable?

Do insiders & institutionals hold more shares of OABI or ALMR?

Summary

How does OmniAb compare to Maravai LifeSciences?

Do institutionals & insiders believe in MRVI or OABI?

Does the media prefer MRVI or OABI?

Which has stronger valuation & earnings, MRVI or OABI?

Do analysts prefer MRVI or OABI?

Is MRVI or OABI more profitable?

Which has more risk & volatility, MRVI or OABI?

Summary

How does OmniAb compare to Personalis?

Which has preferable earnings & valuation, PSNL or OABI?

Do analysts prefer PSNL or OABI?

Does the media favor PSNL or OABI?

Which has more risk & volatility, PSNL or OABI?

Do insiders & institutionals believe in PSNL or OABI?

Is PSNL or OABI more profitable?

Summary

How does OmniAb compare to BioLife Solutions?

Is BLFS or OABI more profitable?

Which has more volatility and risk, BLFS or OABI?

Which has preferable valuation and earnings, BLFS or OABI?

Do analysts recommend BLFS or OABI?

Do institutionals and insiders believe in BLFS or OABI?

Does the media prefer BLFS or OABI?

Summary

How does OmniAb compare to Fortrea?

Do institutionals & insiders hold more shares of OABI or FTRE?

Do analysts recommend OABI or FTRE?

Which has preferable earnings & valuation, OABI or FTRE?

Does the media refer more to OABI or FTRE?

Is OABI or FTRE more profitable?

Which has more volatility & risk, OABI or FTRE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

OABI vs. The Competition

OmniAb Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools